Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Enhanced peer-group strategies to support the prevention of mother-to-child HIV transmission leads to increased retention in care in Uganda: A randomized controlled trial.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: San Francisco, CA : Public Library of Science
    • الموضوع:
    • نبذة مختصرة :
      Introduction: Despite the scale-up of Option B+, long-term retention of women in HIV care during pregnancy and the postpartum period remains an important challenge. We compared adherence to clinic appointments and antiretroviral therapy (ART) at 6 weeks, 6, and and 24 months postpartum among pregnant women living with HIV and initiating Option B+. Women were randomized to a peer group support, community-based drug distribution and income-generating intervention called "Friends for Life Circles" (FLCs) versus the standard of care (SOC). Our secondary outcome was infant HIV status and HIV-free survival at 6 weeks and 18 months postpartum.
      Methods: Between 16 May 2016 and 12 September 2017, 540 ART-naïve pregnant women living with HIV at urban and rural health facilities in Uganda were enrolled in the study at any gestational age. Participants were randomized 1:1 to the unblinded FLC intervention or SOC at enrolment and assessed for adherence to the prevention of mother-to-child HIV transmission (PMTCT) clinic appointments at 6 weeks, 12, and 24 months postpartum, self-reported adherence to ART at 6 weeks, 6 and 24 months postpartum and supported by plasma HIV-1 RNA viral load (VL) measured at the same time points, retention in care through the end of study, and HIV status and HIV-free survival of infants at 18 months postpartum. The FLC groups were formed during pregnancy within 4 months of enrollment and held monthly meetings in their communites, and were followed up until the last group participant reached 24 months post delivery. We used Log-rank and Chi-Square p-values to test the equality of Kaplan-Meier survival probabilities and hazard rates (HR) for failure to retain in care for any reason by study arm.
      Results: There was no significant difference in adherence to PMTCT clinic visits or to ART or in median viral loads between FLC and SOC arms at any follow-up time points. Retention in care through the end of study was high in both arms but significantly higher among participants randomized to FLC (86.7%) compared to SOC (79.3%), p = 0.022. The adjusted HR of visit dropout was 2.4 times greater among participants randomized to SOC compared to FLC (aHR = 2.363, 95% CI: 1.199-4.656, p = 0.013). Median VL remained < 400 copies/ml in both arms at 6 weeks, 6, and 24 months postpartum. Eight of the 431 infants tested at 18 months were HIV positive (1.9%), however, this was not statistically different among mothers enrolled in the FLC arm compared to those in the SOC arm. At 18 months, HIV-free survival of children born to mothers in the FLC arm was significantly higher than that of children born to mothers in the SOC arm.
      Conclusions: Our findings suggest that programmatic interventions that provide group support, community-based ART distribution, and income-generation activities may contribute to retention in PMTCT care, HIV-free survival of children born to women living with HIV, and ultimately, to the elimination of mother-to-child HIV transmission (EMTCT).
      Trial Registration: NCT02515370 (04/08/2015) on ClinicalTrials.gov.
      Competing Interests: PM received funding from NIH/Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) grant # IR01HD080476-01.
      (Copyright: © 2024 Amone et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
    • Comments:
      Update of: medRxiv. 2023 Apr 17;:. (PMID: 37131665)
    • References:
      AIDS Behav. 2017 Feb;21(2):450-461. (PMID: 27278548)
      J Acquir Immune Defic Syndr. 2018 Apr 15;77(5):427-438. (PMID: 29287029)
      BMC Public Health. 2019 Jul 15;19(1):950. (PMID: 31307455)
      J Int AIDS Soc. 2021 Nov;24(11):e25843. (PMID: 34797955)
      PLoS One. 2017 Jul 12;12(7):e0181096. (PMID: 28704472)
      BMC Pregnancy Childbirth. 2019 Aug 13;19(1):288. (PMID: 31409297)
      Pan Afr Med J. 2020 Feb 19;35:49. (PMID: 32537054)
      PLoS One. 2021 Jun 17;16(6):e0252623. (PMID: 34138897)
      BMJ Open. 2019 Jul 29;9(7):e024907. (PMID: 31362959)
      Clin Infect Dis. 2016 Nov 1;63(9):1227-1235. (PMID: 27461920)
      Lancet HIV. 2020 Nov;7(11):e762-e771. (PMID: 32891234)
      PLoS One. 2022 Jun 24;17(6):e0270180. (PMID: 35749510)
      PLoS One. 2021 May 5;16(5):e0251181. (PMID: 33951109)
      J Infect Public Health. 2022 Oct;15(10):1053-1060. (PMID: 36063721)
      Public Health. 2022 Oct;211:105-113. (PMID: 36058198)
      J Acquir Immune Defic Syndr. 2017 May 1;75 Suppl 1:S36-S42. (PMID: 28398995)
      Int J Infect Dis. 2018 Sep;74:71-82. (PMID: 30003952)
      J Glob Health. 2021 Jul 10;11:11001. (PMID: 34327001)
      PLOS Glob Public Health. 2022 Mar 9;2(3):e0000256. (PMID: 36962367)
      J Acquir Immune Defic Syndr. 2014 Nov 1;67 Suppl 2:S114-9. (PMID: 25310116)
      BMC Pregnancy Childbirth. 2019 Jan 16;19(1):32. (PMID: 30651080)
      Front Public Health. 2020 Jan 17;7:401. (PMID: 32010656)
      Lancet HIV. 2016 Apr;3(4):e175-82. (PMID: 27036993)
      J Acquir Immune Defic Syndr. 2016 Aug 1;72 Suppl 2:S124-9. (PMID: 27355499)
      BMC Med Res Methodol. 2019 Jan 7;19(1):4. (PMID: 30616508)
      Int J Gynaecol Obstet. 2022 Nov;159(2):343-350. (PMID: 35122429)
      J Acquir Immune Defic Syndr. 2017 Jun 1;75 Suppl 2:S140-S148. (PMID: 28498183)
      BMC Health Serv Res. 2019 Apr 2;19(1):210. (PMID: 30940149)
      N Engl J Med. 2016 Nov 3;375(18):1726-1737. (PMID: 27806243)
      BMC Pregnancy Childbirth. 2018 Oct 25;18(1):418. (PMID: 30359239)
    • Grant Information:
      R01 HD080476 United States HD NICHD NIH HHS
    • Molecular Sequence:
      ClinicalTrials.gov NCT02515370
    • الرقم المعرف:
      0 (Anti-HIV Agents)
    • الموضوع:
      Date Created: 20240419 Date Completed: 20240422 Latest Revision: 20240506
    • الموضوع:
      20240506
    • الرقم المعرف:
      PMC11029615
    • الرقم المعرف:
      10.1371/journal.pone.0297652
    • الرقم المعرف:
      38640123